Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia

Tomiki Sumiyoshi*, Dai Jin, Karu Jayathilake, Myung Lee, Herbert Y. Meltzer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

We previously reported that plasma levels of glycine, a co-agonist at N-methyl-o-asparate (NMDA)-type glutamate receptors, are decreased in patients with schizophrenia, and that glycine levels are negatively correlated with negative symptoms. The aim of the present study was to determine if glycine, or its ratio to serine, a precursor of glycine, predicts change in negative symptoms in subjects with schizophrenia during treatment with clozapine, an atypical antipsychotic drug with multiple effects on glutamatergic activity. Plasma levels of glycine, serine, and their ratio, were measured in 44 patients with schizophrenia who were subsequently treated with clozapine. Baseline glycine levels or glycine/serine ratios predicted the Scale for the Assessment of Negative Symptoms - Sum of the Global Scales and Avolition-Apathy after 6 wk of clozapine treatment. These results indicate the association of these amino acid measures with response to clozapine in terms of negative symptoms in patients with schizophrenia.

Original languageEnglish (US)
Pages (from-to)451-455
Number of pages5
JournalInternational Journal of Neuropsychopharmacology
Volume8
Issue number3
DOIs
StatePublished - Sep 2005

Keywords

  • Clozapine
  • Glycine
  • Negative symptoms
  • Schizophrenia
  • Serine

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia'. Together they form a unique fingerprint.

Cite this